Related Experiment Video
Updated: Nov 2, 2025
08:40
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
17.8K
Interactions between m6A modification and miRNAs in malignant tumors.
Xiao Han1, Jing Guo2, Zhipeng Fan3,4
1Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Beijing, 100050, China.
Cell Death & Disease
|June 10, 2021
Summary
RNA m6A methylation, a key epigenetic mark, regulates gene expression and impacts cancer. This review explores its role in microRNA (miRNA) biosynthesis and potential anti-cancer therapies.
Area of Science:
- Epigenetics
- Molecular Biology
- Oncology
Background:
- Epigenetic modifications, particularly RNA N6-methyladenosine (m6A) methylation, are increasingly recognized for their regulatory roles in cancer development.
- m6A is the most prevalent RNA modification in eukaryotes, influencing RNA metabolism including transcription, processing, splicing, degradation, and translation.
- MicroRNAs (miRNAs) are crucial biomarkers for disease diagnosis, treatment, and anti-tumor drug development.
Purpose of the Study:
- To review the enzyme systems involved in RNA m6A methylation.
- To elucidate the intricate crosstalk between m6A modification and miRNA biosynthesis in the context of cancer.
- To discuss the future clinical applications and research directions in this rapidly evolving field.
Main Methods:
- Literature review and synthesis of existing research on RNA m6A methylation.
- Analysis of the molecular mechanisms linking m6A modification to miRNA biogenesis.
- Exploration of the interplay between m6A-modified miRNAs and cancer progression.
Main Results:
- RNA m6A methylation enzymes and their regulatory networks are detailed.
- Significant evidence highlights m6A's critical role in modulating miRNA transcription and processing.
- The review establishes a strong connection between m6A-mediated miRNA regulation and various cancers.
Conclusions:
- RNA m6A methylation is a key regulator of miRNA biosynthesis with profound implications in oncology.
- Targeting the m6A-miRNA axis presents promising avenues for novel cancer diagnostics and therapeutics.
- Further research into this crosstalk is essential for advancing personalized cancer medicine.
Related Concept Videos
01:22MicroRNAs
3.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
01:22MicroRNAs
22.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.6K
02:23Abnormal Proliferation
4.8K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
03:03mTOR Signaling and Cancer Progression
4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.0K
02:17The Tumor Microenvironment
7.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
02:39lncRNA - Long Non-coding RNAs
9.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K